The GLOW peptide blend is an injectable mix of three peptides: GHK-Cu, BPC-157 and TB-500. It is marketed for skin, hair and injury recovery, usually in a 70 mg vial labeled for research use only.[31] No human or animal study has tested GLOW as a blend, and none of its injectable ingredients is FDA-approved.[30][7]
This guide breaks down each ingredient, separates human evidence from animal and lab findings, and covers side effects, dosage and the fast-changing regulatory picture. For related compounds, see our healing and skin peptides hub and the KLOW blend, which adds a fourth peptide.
What is the GLOW peptide blend?
Sellers commonly list GLOW as 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500 in one vial.[31] Those amounts come from seller listings, not from any study. The idea is that the three peptides work together on skin and tissue repair, but that has not been tested.[30]
| Ingredient | What it is | Best human evidence |
|---|---|---|
| GHK-Cu | A copper-binding tripeptide found naturally in blood[14] | Small topical skin trials[16][17] |
| BPC-157 | A 15-amino-acid peptide based on a protein in stomach juice[2] | Three small uncontrolled pilot studies[2] |
| TB-500 | A 7-amino-acid fragment of the protein thymosin beta-4[9] | None for TB-500 itself[7] |
What’s in GLOW: the evidence for each ingredient
GHK-Cu (copper peptide)
GHK was first isolated from human blood plasma. In lab dishes, its copper form stimulated collagen production by skin cells.[14] Its discoverer’s reviews report that GHK levels fall with age and that it influences thousands of genes involved in skin repair.[15]
Human evidence is thin. In a small randomized trial after laser skin resurfacing, a GHK-Cu cream did not improve redness, wrinkles or skin quality on objective measures; only patient satisfaction was better.[16] A 2026 systematic review found just two randomized trials among 20 studies.[17] There are no published human trials of injected GHK-Cu.[18]
BPC-157
BPC-157 is a synthetic peptide derived from a protein in human gastric juice, developed by researchers in Zagreb, Croatia.[2][3] In rats, it sped healing of a cut Achilles tendon.[3] A 2025 systematic review of 36 studies found that 35 were in animals, and it found no clinical safety data.[1]
The human studies are small and uncontrolled:
- Knee pain: in a chart review of 16 patients given knee injections, 14 reported improvement, but there was no comparison group and no validated scoring.[4]
- Bladder pain (interstitial cystitis): 10 of 12 women reported complete symptom relief after one 10 mg injection into the bladder wall, again with no control group.[5]
- IV safety: two adults given 10 mg and then 20 mg by IV showed no measurable changes in heart, liver, kidney, thyroid or blood sugar tests.[6]
- Ulcerative colitis: in a 1990s–2000s Croatian trial, a BPC-157 enema did not clearly outperform placebo, according to FDA’s review of the meeting abstract.[7][29]
TB-500
TB-500 is a short, lab-made fragment (Ac-LKKTETQ) of thymosin beta-4, the part of the protein that binds actin.[9] FDA found no studies in which TB-500 was given to people, and no animal toxicity studies.[7]
The full-length protein, thymosin beta-4, has been tested in people as eye drops and skin gels. It improved symptoms of severe dry eye in a 9-person phase 2 trial[11], and in a trial in Italy and Poland, a topical gel was as safe as placebo and may have sped healing of leg ulcers[12]. IV doses were well tolerated in healthy volunteers.[13] Those results do not automatically apply to the TB-500 fragment.
GLOW peptide benefits: claims vs evidence
| Claimed benefit | What the evidence shows |
|---|---|
| Glowing, firmer skin | GHK-Cu raises collagen in lab cells[14]; topical human trials are small and mixed[16][17] |
| Faster injury and tendon healing | Strong results in rats[3]; human data are uncontrolled pilots[1][4] |
| Better results from combining peptides | The only combination study, in rats, found BPC-157 plus TB-500 worked no better than either alone[10] |
| Hair growth | No published human trials of GLOW or its ingredients for hair |
GLOW research around the world
- Croatia: BPC-157 was developed in Zagreb, where the same research group ran early trials for inflammatory bowel disease.[29]
- Russia: researchers in Kursk tested GHK (without copper) and two modified versions on infected wounds in rats. GHK alone did not significantly speed healing, while one modified version shrank wounds by about 92% at day 10.[28]
- China: a 2020 toxicology study in four animal species called BPC-157 well tolerated[26], and a pharmacokinetic study found it lasts under 30 minutes in the blood of rats and dogs[27]. A Chinese phase 1 trial found a recombinant form of thymosin beta-4 well tolerated in healthy volunteers.[33]
- Türkiye: the only animal study combining BPC-157 and TB-500 found no added benefit for tendon healing.[10]
- Italy and Poland: topical thymosin beta-4 was tested for leg ulcers.[12]
What users report
Side effects and safety
No study has measured the side effects of GLOW. What is known about its ingredients:
- Mild effects in small human studies: no serious side effects were reported in the BPC-157 pilots, though safety monitoring was limited. Healthy volunteers given BPC-157 enemas most often reported headache and gas.[7]
- FDA adverse event reports: FDA described three BPC-157 reports with unclear cause: nine days of injection-site redness and swelling, shortness of breath leading to an ER visit, and darkening of the skin and gums that returned when the person used BPC-157 with TB-500 again.[7]
- Animal toxicology: the developers’ 2020 study called BPC-157 well tolerated[26], but FDA read the same data as showing possible blood-clotting and liver-related signals[7].
- Theoretical risks: BPC-157 and thymosin beta-4 promote new blood vessel growth, and a 2026 review lists abnormal blood vessel growth and cancer among potential risks of unregulated use. These risks are theoretical, not observed in people.[2][25]
- Product quality: FDA’s main concerns for all three ingredients are immune reactions to impurities or clumped peptide, and uncertainty about what is in the vial.[19]
GLOW peptide dosage
No dose of the GLOW blend has been studied in people or animals.[30] These are the doses used in published human studies of the individual ingredients:
| Ingredient | Doses studied in humans |
|---|---|
| BPC-157 | 10 mg single injection into the bladder[5]; 10 mg then 20 mg by IV in two adults[6] |
| TB-500 | None[7] |
| Thymosin beta-4 (full protein, not TB-500) | 42 to 1,260 mg by IV in healthy volunteers[13] |
| GHK-Cu | Topical creams only; no injected doses studied[18] |
For converting a vial’s milligrams into syringe units, use our peptide calculator.
Is GLOW FDA approved or legal?
- Not FDA-approved. BPC-157 and TB-500 are not part of any approved drug.[7]
- 2023: FDA put BPC-157, TB-500 and injectable GHK-Cu on its list of substances that may pose significant safety risks in compounding.[19]
- April 2026: after the nominations were withdrawn, FDA removed them from that list. That did not approve them.[19][20]
- May 2026: GHK-Cu for non-injectable uses (such as creams) returned to the list of substances FDA is evaluating for compounding.[20]
- July 2026: FDA’s compounding advisory committee reviewed BPC-157 and TB-500.[21] FDA recommended against allowing them, but the committee reportedly voted 8 to 6 in favor of each.[8][22] The vote is not binding, and no rule had followed as of our last review.
- Sport: WADA bans BPC-157 as a non-approved substance and TB-500 as a growth factor, at all times. GHK-Cu is not named.[23][24]
This is general information, not legal advice.
GLOW vs KLOW
KLOW is GLOW plus KPV, a small anti-inflammatory peptide. KPV has been studied only in animals and cell cultures, so adding it does not change the overall evidence picture.